Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy
Neoadjuvant chemotherapy has been established as standard treatments for advanced breast cancer among multidisciplinary therapies. A simple and instructive biomarker for the postoperative recurrence and metastasis is needed to evaluate the therapeutic effect. Plasma fibrinogen level has been shown t...
Saved in:
| Main Authors: | Yu Mei, Haixia Liu, Xiaorong Sun, Xiangyi Li, Song Zhao, Rong Ma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317700002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy
by: Eda Caliskan Yildirim, et al.
Published: (2025-03-01) -
Inflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy
by: Yiwen Sun, et al.
Published: (2025-07-01) -
Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy
by: Youzhao Ma, et al.
Published: (2024-12-01) -
Adjuvant Chemotherapy May be Waived for Breast Cancer Nonresponders to Neoadjuvant Chemotherapy: A Population‐Based Large Cohort Study
by: Lixi Li, et al.
Published: (2025-05-01) -
Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
by: Nicole M. Melchior, et al.
Published: (2020-04-01)